Does the media favor MNKD or CLDX?

In the previous week, MannKind had 12 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for MannKind and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat MannKind's score of 0.73 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MNKD or BCRX?

In the previous week, MannKind had 10 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 14 mentions for MannKind and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat MannKind's score of 0.73 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, INVA or MNKD?

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.84 $271.17M $6.01 3.56 MannKind $348.97M 3.34 $5.86M -$0.07 N/A

Is INVA or MNKD more profitable?

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 119.89% 33.33% 22.67% MannKind -6.63% -11.21% -3.92%

Does the media refer more to INVA or MNKD?

In the previous week, MannKind had 10 more articles in the media than Innoviva. MarketBeat recorded 14 mentions for MannKind and 4 mentions for Innoviva. MannKind's average media sentiment score of 0.73 beat Innoviva's score of 0.58 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NVAX or MNKD?

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.61 $440.30M -$0.58 N/A MannKind $348.97M 3.34 $5.86M -$0.07 N/A

Is NVAX or MNKD more profitable?

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% MannKind -6.63% -11.21% -3.92%

Does the media refer more to NVAX or MNKD?

In the previous week, Novavax had 2 more articles in the media than MannKind. MarketBeat recorded 16 mentions for Novavax and 14 mentions for MannKind. MannKind's average media sentiment score of 0.73 beat Novavax's score of 0.70 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBIO or MNKD?

In the previous week, MannKind had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 14 mentions for MannKind and 3 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.73 beat Zenas BioPharma's score of 0.62 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

MannKind (MNKD) Competitors

$3.77 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$3.66 -0.11 (-3.00%)

As of 04:57 AM Eastern

Compare

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

Should you buy MannKind stock or one of its competitors? MarketBeat compares MannKind with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MannKind include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry.

How does MannKind compare to Celldex Therapeutics?

MannKind (NASDAQ:MNKD) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, MannKind had 12 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for MannKind and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat MannKind's score of 0.73 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

MannKind has higher revenue and earnings than Celldex Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.34	$5.86M	-$0.07	N/A
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Celldex Therapeutics	N/A	-50.72%	-46.59%

MannKind presently has a consensus price target of $8.97, suggesting a potential upside of 137.90%. Celldex Therapeutics has a consensus price target of $49.78, suggesting a potential upside of 58.38%. Given MannKind's higher probable upside, research analysts clearly believe MannKind is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

MannKind beats Celldex Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to BioCryst Pharmaceuticals?

MannKind (NASDAQ:MNKD) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

49.6% of MannKind shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MannKind presently has a consensus target price of $8.97, indicating a potential upside of 137.90%. BioCryst Pharmaceuticals has a consensus target price of $20.70, indicating a potential upside of 132.32%. Given MannKind's higher possible upside, equities research analysts plainly believe MannKind is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

MannKind has a net margin of -6.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. MannKind's return on equity of -11.21% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

In the previous week, MannKind had 10 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 14 mentions for MannKind and 4 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 0.91 beat MannKind's score of 0.73 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.34	$5.86M	-$0.07	N/A
BioCryst Pharmaceuticals	$874.84M	2.59	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Innoviva?

Innoviva (NASDAQ:INVA) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Innoviva has a net margin of 119.89% compared to MannKind's net margin of -6.63%. Innoviva's return on equity of 33.33% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
MannKind	-6.63%	-11.21%	-3.92%

Innoviva has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Innoviva has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.84	$271.17M	$6.01	3.56
MannKind	$348.97M	3.34	$5.86M	-$0.07	N/A

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Innoviva currently has a consensus price target of $36.20, suggesting a potential upside of 69.00%. MannKind has a consensus price target of $8.97, suggesting a potential upside of 137.90%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, MannKind had 10 more articles in the media than Innoviva. MarketBeat recorded 14 mentions for MannKind and 4 mentions for Innoviva. MannKind's average media sentiment score of 0.73 beat Innoviva's score of 0.58 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats MannKind on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Novavax?

Novavax (NASDAQ:NVAX) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

MannKind has a net margin of -6.63% compared to Novavax's net margin of -14.73%. MannKind's return on equity of -11.21% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
MannKind	-6.63%	-11.21%	-3.92%

Novavax has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.61	$440.30M	-$0.58	N/A
MannKind	$348.97M	3.34	$5.86M	-$0.07	N/A

Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, MannKind has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Novavax presently has a consensus target price of $12.13, indicating a potential upside of 10.53%. MannKind has a consensus target price of $8.97, indicating a potential upside of 137.90%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Novavax had 2 more articles in the media than MannKind. MarketBeat recorded 16 mentions for Novavax and 14 mentions for MannKind. MannKind's average media sentiment score of 0.73 beat Novavax's score of 0.70 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

53.0% of Novavax shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 1.6% of Novavax shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

MannKind beats Novavax on 9 of the 16 factors compared between the two stocks.

How does MannKind compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
MannKind	-6.63%	-11.21%	-3.92%

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	116.16	-$377.74M	-$8.47	N/A
MannKind	$348.97M	3.34	$5.86M	-$0.07	N/A

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 140.68%. MannKind has a consensus price target of $8.97, suggesting a potential upside of 137.90%. Given Zenas BioPharma's higher probable upside, equities analysts clearly believe Zenas BioPharma is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

49.6% of MannKind shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 2.6% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MannKind had 11 more articles in the media than Zenas BioPharma. MarketBeat recorded 14 mentions for MannKind and 3 mentions for Zenas BioPharma. MannKind's average media sentiment score of 0.73 beat Zenas BioPharma's score of 0.62 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market. Comparatively, MannKind has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Summary

MannKind beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.16B	$3.40B	$6.40B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-53.85	18.88	21.59	26.27
Price / Sales	3.34	334.85	555.66	114.93
Price / Cash	60.93	54.19	27.44	37.60
Price / Book	-22.18	6.93	10.07	6.86
Net Income	$5.86M	$24.20M	$3.56B	$337.26M
7 Day Performance	11.54%	4.11%	2.84%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	-9.38%	66.00%	37.64%	39.67%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	4.2647 of 5 stars	$3.77 flat	$8.97 +137.9%	-9.4%	$1.16B	$348.97M	N/A	400	Analyst Forecast Gap Down High Trading Volume
CLDX Celldex Therapeutics	2.4287 of 5 stars	$30.73 flat	$49.78 +62.0%	+61.3%	$2.41B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1168 of 5 stars	$8.29 flat	$20.70 +149.7%	-17.0%	$2.11B	$874.84M	N/A	530
INVA Innoviva	3.5815 of 5 stars	$22.46 flat	$36.20 +61.2%	+9.1%	$1.66B	$411.33M	3.74	100
NVAX Novavax	1.7285 of 5 stars	$9.21 flat	$12.13 +31.7%	+48.4%	$1.51B	$1.12B	N/A	1,990	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does MannKind compare to Celldex Therapeutics?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Summary

How does MannKind compare to Innoviva?

Summary

How does MannKind compare to Novavax?

Summary

How does MannKind compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. CLDX, BCRX, INVA, NVAX, and ZBIO

How does MannKind compare to Celldex Therapeutics?

Does the media favor MNKD or CLDX?

Which has more volatility & risk, MNKD or CLDX?

Which has stronger earnings and valuation, MNKD or CLDX?

Is MNKD or CLDX more profitable?

Do analysts rate MNKD or CLDX?

Do institutionals & insiders have more ownership in MNKD or CLDX?

Summary

How does MannKind compare to BioCryst Pharmaceuticals?

Do institutionals and insiders believe in MNKD or BCRX?

Do analysts rate MNKD or BCRX?

Is MNKD or BCRX more profitable?

Which has more volatility and risk, MNKD or BCRX?

Does the media prefer MNKD or BCRX?

Which has preferable earnings and valuation, MNKD or BCRX?

Summary

How does MannKind compare to Innoviva?

Is INVA or MNKD more profitable?

Which has more risk and volatility, INVA or MNKD?

Which has preferable earnings and valuation, INVA or MNKD?

Do insiders and institutionals hold more shares of INVA or MNKD?

Do analysts prefer INVA or MNKD?

Does the media refer more to INVA or MNKD?

Summary

How does MannKind compare to Novavax?

Is NVAX or MNKD more profitable?

Which has higher earnings & valuation, NVAX or MNKD?

Which has more risk and volatility, NVAX or MNKD?

Do analysts rate NVAX or MNKD?

Does the media refer more to NVAX or MNKD?

Do institutionals & insiders believe in NVAX or MNKD?

Summary

How does MannKind compare to Zenas BioPharma?

Is ZBIO or MNKD more profitable?

Which has higher earnings and valuation, ZBIO or MNKD?

Do analysts rate ZBIO or MNKD?

Do institutionals & insiders believe in ZBIO or MNKD?

Does the media favor ZBIO or MNKD?

Which has more volatility & risk, ZBIO or MNKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools